Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaFRA:IP40 +2.97%58 Net Cash per Share is €0.19 as of Mar. 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 58/100 and a GF Value™ of €9.60 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 325 Consumer Packaged Goods companies, InnoCan Pharma ranks better than 53.54% on this metric.
The historical rank and industry rank for InnoCan Pharma's Net Cash per Share or its related term are showing as below:
FRA:IP40'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.5 Med: 21.67 Max: 190.36
Current: 8.15
During the past 8 years, the highest Price-to-Net-Cash Ratio of InnoCan Pharma was 190.36. The lowest was 7.50. And the median was 21.67.
FRA:IP40's Price-to-Net-Cash is ranked better than 53.54% of 325
companies
in the Consumer Packaged Goods industry
Industry Median: 8.35
vs FRA:IP40: 8.15
InnoCan Pharma (FRA:IP40) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
InnoCan Pharma Net Cash per Share Related Terms
InnoCan Pharma Net Cash per Share Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IP40 vs PG, CL, KVUE: Net Cash per Share Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Price-to-Net-Cash vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
InnoCan Pharma's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (FRA:IP40) has a Net Cash per Share of €0.19 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #151 out of 325 companies in the Consumer Packaged Goods industry, placing it in the top 46.5%.
Is InnoCan Pharma's Net Cash per Share too high?
InnoCan Pharma's current Net Cash per Share is €0.19. Based on the distribution chart, InnoCan Pharma ranks #151 out of 325 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, InnoCan Pharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Net Cash per Share compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #151 out of 325 companies for Net Cash per Share. This puts InnoCan Pharma in the upper half of its industry. The industry median Net Cash per Share is 8.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Consumer Packaged Goods company?
The median Net Cash per Share among Consumer Packaged Goods companies is 8.35, based on 325 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Net Cash per Share is 8.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Net Cash per Share is €0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.60, compared to a current price of €1.39 — trading 85.6% below its estimated fair value. The current Net Cash per Share is €0.19. InnoCan Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Net Cash per Share is €0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.39 is trading 85.6% below its estimated GF Value™ of €9.60.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for FRA:IP40:
Net Cash per Share: €0.19
GF Value™: €9.60 vs. price of €1.39 (85.6% below fair value)
No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
58GF Score
Get the complete analysis for FRA:IP40
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IP40 has been successfully added to your 
